CEP-18770
C18770/2049
Phase 2 small_molecule completed
Quick answer
CEP-18770 for Multiple Myeloma is a Phase 2 program (small_molecule) at Teva Generics B.V with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Generics B.V
- Indication
- Multiple Myeloma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed